GSK strikes $1 billion licensing, development deal for potential hepatitis B treatment
GSK will pay some $1 billion to acquire rights to and commercialize an hepatitis B therapy from Johnson & Johnson in a deal announced Tuesday.
Read More
hepatitis B
